πŸ‡ΊπŸ‡Έ FDA
Patent

US 10377772

Macrocyclic LRRK2 kinase inhibitors

granted A61PA61P25/16A61P25/28

Quick answer

US patent 10377772 (Macrocyclic LRRK2 kinase inhibitors) held by Oncodesign SA expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Oncodesign SA
Grant date
Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61P, A61P25/16, A61P25/28, A61P43/00